AFRM IMPORTANT DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Affirm Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 6 Deadline in Securities Class Action – AFRM

NEW YORK, Feb. 4, 2023 /PRNewswire/ — 

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Affirm Holdings, Inc. (NASDAQ: AFRM) between February 12, 2021 and December 15, 2021, both dates inclusive (the “Class Period”), of the important February 6, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Affirm securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Affirm class action, go to https://rosenlegal.com/submit-form/?case_id=3161 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 6, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Affirm’s BNPL service facilitated excessive consumer debt, regulatory arbitrage, and data harvesting; (2) the foregoing subjected Affirm to a heightened risk of regulatory scrutiny and enforcement action; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Affirm class action, go to https://rosenlegal.com/submit-form/?case_id=3161 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

SOURCE Rosen Law Firm, P.A.

ENOVIX SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Enovix To Contact Him Directly To Discuss Their Options

NEW YORK, Feb. 4, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Enovix Corp. f/k/a Rodgers Silicon Valley Acquisition Corp. (“Enovix” or the “Company”) (NASDAQ: ENVX, RSVA) and reminds investors of the March 7, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in Enovix stock or options between February 22, 2021 and January 3, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ENVX.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Enovix designs, develops, and manufactures silicone-anode lithium ion batteries using proprietary 3D cell architecture, which the Company claims allow its batteries to achieve higher energy density. On July 15, 2021, Enovix became a publicly traded company by merging with a special purpose acquisition company (“SPAC”), after being acquired by the Rodgers Silicon Valley Acquisition Corp. (“RSVAC”) on July 14, 2021.

At the time Enovix went public, the Company’s only manufacturing line was beset by defects and technical problems that prevented the Enovix from manufacturing its batteries at scale, despite then CEO, Harrold Rust’s stating that the Company was focused on producing for “mass-market applications.”

Throughout the class period, defendants overstated Enovix’s ability to produce batteries at scale, touting the Company’s “meaningful progress” in scaling up its manufacturing facility, and its being positioned to deliver batteries ahead of competitions, despite its continued manufacturing issues.

On November 1, 2022, Enovix released a Letter to Shareholders for Q3 2022 in which it reported third quarter revenue of only eight thousand dollars, despite prior promises of delivery commercial products on a meaningful scale. Additionally, the Q3 letter disclosed that Enovix was pivoting and prioritizing its next generation manufacturing lines, altering previously announced commercialization timelines.

Following these disclosures, Enovix shares plummeted 44% from its October 31, 2022 closing price to when the market closed on November 2, 2022.

Then on January 3, 2023, Enovix held a “special presentation to shareholders” during which new CEO Thurman Rodgers disclosed further issues with both productions lines, with one line “doing less than 10% of what it should be doing,” and that revenues investors had previously been told to expect in early 2024 were no longer possible due to buildout delays.

On this news, Enovix shares plunged 41% in intraday trading on January 4, 2023.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Enovix’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

ARTIFICIAL BLOOD PRODUCT ONE STEP CLOSER TO REALITY WITH $46 MILLION IN FEDERAL FUNDING

Funding Will Be Used to Develop Shelf-Stable Product for Trauma Patients to Potentially Save Lives

BALTIMORE, Feb. 4, 2023 /PRNewswire/ — A University of Maryland School of Medicine (UMSOM) physician-scientist will head a new federally-funded research program to develop and test a whole blood product, storable at room temperature, that can be used to transfuse wounded soldiers in the field within 30 minutes of injury, potentially saving thousands of lives. UMSOM will manage the $46.4 million four-year research project administered by the Defense Advanced Research Projects Agency (DARPA), in collaboration with the University of Maryland School of Pharmacy (UMSOP) and more than a dozen universities and biotech companies.

“We have assembled an outstanding team to develop a bio-synthetic whole-blood product that can be freeze-dried for easy portability, storage, and reconstitution,” said study principal investigator Allan Doctor, MD, Professor of Pediatrics and Director of the Center for Blood Oxygen Transport and Hemostasis (CBOTH) at UMSOM. “It will be designed for easy use in the field by medics at the point of injury, and will perform like a traditional blood transfusion to, for example, stabilize a patient’s blood pressure or facilitate blood clotting.”

To achieve this goal, the program will employ sophisticated artificial intelligence, state-of-the-art experimental platforms, and multiple complimentary animal models. The product will be tested for efficacy and safety in trauma victims who have complex multiple injuries including shock and traumatic brain injury.

Bleeding is the most common cause of potentially survivable death in trauma, in both military and civilian settings. Whole blood transfusions remain the gold standard but present logistical challenges such as the dependence on available donors, requirement for cold storage, and limited viability of about 40 days. Rapid evacuation of patients who are rapidly bleeding out due to a gunshot wound or other trauma is not always an option. For this reason, there is an urgent need for an artificial blood product with a long shelf life that is easy to transport.

To conduct this project, Dr. Doctor has assembled a consortium comprising faculty members from UMSOM and UMSOP to work on the artificial oxygen carrier (red blood cell) component that he pioneered in earlier studies and on pharmacology, computational modeling, and machine learning to optimize the combined product, which will also include synthetic platelets and freeze-dried plasma.

This product will consist of ErythroMer, the artificial blood product made by KaloCyte, a company co-founded by Dr. Doctor in 2016 with bioengineer and synthetic chemist Dipanjan Pan, PhD, MSc, Professor in nano medicine at Penn State University, and Philip Spinella, MD, a military transfusion medicine expert at the University of Pittsburgh.

It will also include a synthetic platelet product developed by Anirban Sen Gupta, PhD of Case Western Reserve University that is under development by Haima Therapeutics and a freeze-dried plasma product made by Telefex.

Dr. Doctor is a founding partner, Chief Scientific Officer, and Chair of the Board of Directors for KaloCyte, which could potentially benefit from this research. His interest in the company has been reviewed in accordance with the university’s conflicts of interest policy to ensure objectivity in the research.

“We are well-positioned to support this highly complex project that requires the use of advanced modeling and simulation, and a machine learning software system to optimize the prototypes and to test for safety and efficacy in models of complex trauma with multiple complications,” said study co-investigator Joga Gobburu, PhD, MBA, Professor of Practice, Sciences, and Health Outcomes Research, and Director of the Center for Translational Medicine at UMSOP.

The first phase of the study will be to integrate multiple bio-artificial and synthetic components to deliver oxygen, stop bleeding, and replace volume; these are key therapeutic functions of whole blood in resuscitation. In the second phase, the team will evaluate efficacy and safety in increasingly complex and realistic trauma models. This phase will also involve developing strategies for stabilizing the product for months under ambient climate conditions in extreme environments.

Throughout both phases, the team will also plan, develop, and refine manufacturing methods. This will address the real-world pragmatic challenges of production, scaling, packaging, and quality control that must be surmounted to enable effective transition of the developed products to successful clinical trials and, eventually, to safe and efficient clinical utility.

While UMSOM and UMSOP will be leading this effort, the consortium also includes leading scientists and complimentary experts from Case Western Reserve University, Charles River Laboratories, Latham Biopharm Group, Ohio State University, Pumas-AI Inc., Southwest Research Institute, University of California San Diego, University of Pittsburgh, Oregon Health Sciences University, University of Texas Austin and University of North Carolina, in addition to the companies developing the bio-synthetic blood components themselves: Haima Therapeutics, KaloCyte, and Teleflex.

“About 20,000 Americans each year bleed to death before they can be brought to the hospital. Transfusion at the point of injury is required to stablilize them and limit other organ injury,” said UMSOM Dean Mark T. Gladwin, MD, Vice President for Medical Affairs, University of Maryland, Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor. “This project will utilize cutting edge technologies like artificial intelligence to predict interactions among the blood components in various trauma model systems, which would not have been possible a decade ago.”

DARPA’s Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program aims to develop a field-deployable, shelf-stable whole blood equivalent that can be used to resuscitate trauma patients when donated blood products are not available. Other subcontractors have the potential to join the consortium pending the exercise of additional options in the FSHARP award.

About the
University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world — with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.3 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.

SOURCE University of Maryland School of Medicine

NEWAGE SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In NewAge To Contact Him Directly To Discuss Their Options

NEW YORK, Feb. 4, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against NewAge, Inc. (“NewAge” or the “Company”) (OTC: NBEVQ, NASDAQ: NBEV) and reminds investors of the February 6, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in NewAge stock or options between January 18, 2018 and October 18, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/NBEVQ.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) NewAge never entered into a “distribution agreement” or “initiative in partnership” with the military and never had plans to sell its products at all commissaries and exchanges around the world; (2) NewAge did not have adequate inventory of its products to fulfill this reported agreement; (3) NewAge did not actually expand its product lines or distribution agreements as represented; (4) the Company lacked adequate internal controls; (5) as a result the Company had a heightened risk of regularly scrutiny and ultimately subject to an SEC investigation and action; and (6) as a result of the foregoing, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding NewAge’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Zoomlion liefert verschiedene Produktserien im Gesamtwert von mehr als einer Milliarde Yuan (148 Mio. USD) an Kunden weltweit

CHANGSHA, China, 3. Februar 2023 /PRNewswire/ — Am 29. Januar 2023 lieferte Zoomlion Heavy Industry Science & Technology Co, Ltd. (Zoomlion) eine Reihe von Produkten im Gesamtwert von mehr als einer Milliarde Yuan (148 Mio. USD) aus. Die Lieferung ist Teil der internationalen Wachstumsstrategie von Zoomlion und bildet eine solide Grundlage für die Bemühungen des Unternehmens, seine Kernwettbewerbsfähigkeit bis 2023 zu verbessern.

Die technischen Kräne von Zoomlion, darunter mehr als 200 Raupenkräne und Autokräne im Gesamtwert von mehr als 400 Millionen Yuan (60 Mio. USD), wurden gleichzeitig von mehreren Industrieparks geliefert. Der weltweite Auftragseingang von Zoomlion für Krantechnik wächst rasant, und die Nachfrage nach weltweiten Aufträgen wurde bereits bis Ende März bearbeitet.

Zoomlion hat 2022 die neue R-Generation von Turmdrehkränen auf den Markt gebracht und will 2023 die Digitalisierung und intelligente Entwicklung vorantreiben. Neue Maschinen im Wert von fast 100 Mio. Yuan (15 Mio. USD) wurden von den fünf großen Stützpunkten geliefert.

Die Betonmaschinen von Zoomlion, darunter Langarm-Pumpenwagen und Dosieranlagen, standen auch 2022 an erster Stelle des Absatzvolumens im Inland, und eine Reihe von Spitzenprodukten sorgte für einen Umsatzanstieg. Im Januar wurden hochwertige Geräte im Wert von fast 100 Millionen Yuan an Kunden ausgeliefert. 2023 wird Zoomlion die intelligente Herstellung von Pumpenwagen der Serie „Lingyun”, von LKW-montierten Pumpen der Serie „Kunpeng”, von Verteilermasten, Spritzen und Anhängerpumpen beschleunigen.

Der Geschäftsbereich Hubarbeitsbühnen (AWP) des Unternehmens, der mehr als 80 Länder und Regionen auf fünf Kontinenten abdeckt, ist einer der am schnellsten wachsenden Geschäftsbereiche von Zoomlion und ein führender Anbieter in der Branche. Im Januar dieses Jahres wurden Spitzenprodukte im Gesamtwert von mehr als 200 Mio. Yuan (30 Mio. USD) in die ganze Welt geliefert. Im Jahr 2023 wird das Unternehmen in eine neue Phase der raschen und hochwertigen Entwicklung eintreten.

Was die Erdbewegungsmaschinen von Zoomlion betrifft, so wurden fast 200 Bagger und Kompaktlader in verschiedene Regionen Chinas und wichtige Auslandsmärkte geliefert.

Außerdem hat Zoomlion Rammmaschinen, Bergbaumaschinen, Notfallausrüstung, Industriefahrzeuge, Landmaschinen und andere intelligente Maschinen ausgeliefert. Der Bau der Zoomlion Smart Industrial City ist ebenfalls im Gange.

Mit einem positiven Ausblick und einer verbesserten Kernwettbewerbsfähigkeit wird Zoomlion alles daran setzen, Fortschritte zu erzielen und gleichzeitig ein stabiles Wachstum im Jahr 2023 beizubehalten.

Foto – https://mma.prnewswire.com/media/1995533/Zoomlion_Delivers_Various_Series_of_Products_with_a_Total_Value_of_More_Than_One_Billion_Yuan___148.jpg

SOURCE Zoomlion

Joaquin Sabina in USA

2 dates only in USA in November 2023

Tickets on sale today February 3rd

MIAMI, Feb. 3, 2023 /PRNewswire-HISPANIC PR WIRE/– Super star singer songwriter Joaquin Sabina returns to United States for two exclusives dates as he continues his tour “Contra Todo Pronostico” to Latin America. Tickets go on sale today February 3rd in Ticket Master. Beloved Spanish author, poet, singer, and songwriter whose work has influenced four generations of musicians and writers will delight fans with an array of his most popular and favorite songs. A concert for music lovers not to be missed

NOVEMBER 16New York– Hulu Theater
Nyc- https://www.ticketmaster.com/joaquin-sabina-new-york-new-york-11-16-2023/event/3B005E3A84290F33

NOVEMBER 19– Miami Dade Arena
Miamihttps://www.ticketmaster.com/event/0D005E2DC19DE2CB

WITH THE EMPORIO GROUP GUARANTEE

Contact Press & Publicity: Marianne Mendieta [email protected]

Photo – https://mma.prnewswire.com/media/1995769/Joaquin_Sabina_in_USA.jpg

Logo – https://mma.prnewswire.com/media/1908470/Emporio_Group_Logo.jpg

SOURCE Emporio Group

Global Enhanced Vision System Strategic Business Report 2023: Introduction of Innovative Enhanced Vision Systems Drives Growth

DUBLIN, Feb. 3, 2023 /PRNewswire/ — The “Enhanced Vision System – Global Strategic Business Report” report has been added to  ResearchAndMarkets.com’s offering.


The global market for Enhanced Vision System estimated at US$246.5 Million in the year 2022, is projected to reach a revised size of US$323 Million by 2030, growing at a CAGR of 3.4% over the analysis period 2022-2030.

Synthetic Vision Systems, one of the segments analyzed in the report, is projected to record 3.9% CAGR and reach US$190.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Enhanced Vision System segment is readjusted to a revised 2.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $72.1 Million, While China is Forecast to Grow at 3.3% CAGR

The Enhanced Vision System market in the U.S. is estimated at US$72.1 Million in the year 2022. China, the world’s second largest economy, is forecast to reach a projected market size of US$57.5 Million by the year 2030 trailing a CAGR of 3.3% over the analysis period 2022 to 2030.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 2.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Select Competitors (Total 12 Featured) –

  • Astronics Corporation
  • Elbit Systems Ltd.
  • Esterline Technologies Corporation
  • Honeywell International, Inc.
  • L-3 Communications Holdings, Inc.
  • MBDA France
  • Opgal Optronic Industries Ltd.
  • Rockwell Collins, Inc.
  • Thales Group
  • United Technologies Corporation (UTC)

What`s New for 2023?

  • Special coverage on RussiaUkraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies – Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Enhanced Vision System Market: An Overview
  • Enhanced Vision System – Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Continuous Innovation to Sustain Market Demand
  • Necessity for Improved Safety Augur well for the Market Growth
  • Introduction of Technologically Advanced Aircraft Systems to Bode well for the Market
  • Increased Need for Reliable Operations at Poor Visibility Drive Market Growth
  • Smaller Airport Equipped with Inadequate Infrastructure to Propel Market Growth
  • With Several Benefits Associated with Installing Enhanced Vision System, Demand for Enhanced Vision System to Propel
  • Increased Opportunities from Airline Aftermarket to Bode Well for Market Demand
  • Partnership Deals Offer Extended Opportunities for the Market
  • Introduction of Innovative Enhanced Vision Systems: A Growth Driver

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/l8zjwx-vision?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

Chinas größter exportierter Teleskopkran, der XCC2000 von XCMG schließt seinen ersten Einsatz in Europa ab

LIVNO, Bosnien und Herzegowina, 3. Februar 2023 /PRNewswire/ — Mit der Fertigstellung der ersten Windkraftanlage mit 136-Meter-Rotorblättern, die Teil des Windparkprojekts Ivovik in Livno in Bosnien und Herzegowina ist, hat der XCC2000, Chinas größter exportierter Windkraftanlagenkran mit Teleskopausleger, seinen ersten Kraneinsatz in Europa erfolgreich abgeschlossen und die von anderen vergleichbaren Modellen in diesem Sektor aufgestellten Hubrekorde gebrochen. Der XCC2000 ist ein Produkt des Unternehmens XCMG Hoisting Machinery, das weltweit umfassende Produktserien und -varianten anbietet.

Im Rahmen der Konstruktionsphase dieses Windkraftprojekts sollen mit dem XCC2000 zwanzig in China hergestellte Windturbinen mit einer installierten Gesamtkapazität von 84 MW errichtet werden. Dies ist das größte Projekt zur Erzeugung erneuerbarer Energien in Bosnien. Von der lokalen Regierung wurde es als bedeutendes nationales Programm bezeichnet. Es ist auch das größte Energieprojekt, das je von einem chinesischen Unternehmen in dieser Region finanziert und errichtet wurde und stellt darüber hinaus ein wegweisendes Projekt im Rahmen der Initiative „Neue Seidenstraße” in Europa dar. Dieses Projekt wurde auch in die Liste der Errungenschaften des China-Central and Eastern European Leaders Summit 2021 aufgenommen.

Die Baustelle des Windkraftprojekts Ivovik befindet sich etwas mehr als 1.500 Meter über dem Meeresspiegel. Der Großteil der Bauarbeiten findet mitten im bosnischen Winter statt, einer Zeit, die für ihre heftigen Stürme und das unberechenbare Wetter bekannt ist. Dies ist eine echte Bewährungsprobe für den gesamten Hubbetrieb, die strengste Anforderungen an die Hubleistung, die Betriebsmobilität und den Transportzugang der Hebetechnik stellt. Der XCC2000 ist ein wichtiges Gerät bei der Errichtung des Windkraftprojekts Ivovik. Er zeichnet sich durch seine hervorragende Hub- und Umschlagsleistung aus.

Hohe Hubleistung 

Mit einer maximalen Hauptauslegerlänge von 81,4 Metern und einer maximalen Windanlagenauslegerlänge von 80 Metern ist der XCC2000 einer der höchstentwickelten und technologisch fortschrittlichsten 1.000-Tonnen-Megakrane von XCMG. Er kann Lasten bis zu einer Höhe von 150 Metern heben.

Die ausgezeichnete Mobilität des Krans ermöglicht seine einfache Umsetzung auf der gesamten Baustelle 

Mit nur 4,5 m Spurweite seiner Laufwerksketten kann der XCC2000 einen großen Ausleger tragen, der schwere Lasten an verschiedene Stellen auf der Baustelle befördern kann. Damit stellt der Einsatz dieses Krans eine effizientere Möglichkeit zur Installation großer Windturbinen dar, senkt die Kosten für den Bau der Windkraftanlage selbst und steigert die Effizienz während der Bauphase des Projekts.

Zur Gewährleistung eines pünktlichen Projektabschlusses wurde von XCMG ein professionelles Serviceteam zusammengestellt, das einen wissenschaftlich fundierten, systematischen Hubbetriebsplan entwickelte, bei dem der XCC2000 als Hauptkran und zwei geländegängige Krane des Typs XCA130_E als Hilfskrane eingesetzt werden. Die Maschine von XCMG bewährte sich nicht nur in Sturm, Frost, Schnee und Regen, bei starken Minusgraden und unter anderen widrigen Wetterbedingungen während des Kraneinsatzes, sondern schloss die Bauarbeiten auch pünktlich innerhalb der festgelegten Zeit ab. Damit stellte dieser Kran sicher, dass die Turbine effizient und zuverlässig installiert wurde.

„Die extrem hohe Zuverlässigkeit des XCMG-Krans und seine hohe Mobilität auf engstem Raum garantierte die schnelle und präzise Installation der Windkraftanlage unter schwierigen und wechselhaften Wetterbedingungen”, erklärte Yang Jianjun, stellvertretender Geschäftsführer von Youtone, dem Auftragnehmer des Projekts. „Das Serviceteam unterstützte das Projekt auch durch Arbeitsleistungen und Ausrüstungen, weshalb wir uns für XCMG entschieden haben.”

Weitere Informationen zu Hubmaschinen bzw. zum Projekt finden Sie unter XCMG Hubmaschinen.

Foto – https://mma.prnewswire.com/media/1995418/XCC2000.jpg

SOURCE XCMG Hoisting Machinery

Joaquin Sabina in USA

2 dates only in USA in November 2023

Tickets on sale today February 3rd

MIAMI, Feb. 3, 2023 /PRNewswire/ — Super star singer songwriter Joaquin Sabina returns to United States for two exclusives dates as he continues his tour “Contra Todo Pronostico” to Latin America. Tickets go on sale today February 3rd in Ticket Master. Beloved Spanish author, poet, singer, and songwriter whose work has influenced four generations of musicians and writers will delight fans with an array of his most popular and favorite songs. A concert for music lovers not to be missed

NOVEMBER 16New York– Hulu Theater
Nyc- https://www.ticketmaster.com/joaquin-sabina-new-york-new-york-11-16-2023/event/3B005E3A84290F33

NOVEMBER 19– Miami Dade Arena
Miamihttps://www.ticketmaster.com/event/0D005E2DC19DE2CB

WITH THE EMPORIO GROUP GUARANTEE

Contact Press & Publicity: Marianne Mendieta [email protected]

SOURCE Emporio Group

Boston Celtics and Sun Life close out 9th annual Fit to Win youth program with Celtics forward Justin Jackson at trampoline park

WELLESLEY, Mass., Feb. 3, 2023 /PRNewswire/ — Sun Life U.S. and the Boston Celtics on Thursday wrapped another year of Fit to Win, a health and fitness program for YMCA youth, at Launch Trampoline Park in Norwood, Mass. Justin Jackson, along with Lucky the Leprechaun and members of the Celtics Flight Crew, joined the kids for laser tag, dodgeball, a ninja warrior course, and some good old-fashioned bouncing. Fit to Win is a four-week program that teaches kids about fitness, nutrition, and healthy lifestyle habits. The kids track their results and keep mindfulness journals throughout the program.

“Fit to Win still has an impact after nine years because of partners like Sun Life and the YMCA of Greater Boston, both of whom share the Celtics commitment to promoting health and wellness in the community,” said Ted Dalton, Boston Celtics chief partnership officer. “We look forward to continuing this program with Sun Life and the YMCA, and seeing our younger fans get excited about health and fitness.”

During the program, the Celtics and Sun Life hosted the Fit to Win participants at a nutrition event at the Thomas M. Menino YMCA in Hyde Park, where Celtics player Luke Kornet joined the kids in a smoothie making competition. Each group of children submitted their smoothie to a panel of judges, including members of the Celtics nutrition staff, who scored each recipe and crowned the winning smoothie.

“Bringing programs like Fit to Win to the YMCA of Greater Boston is part of Sun Life’s commitment to helping more people access health services that can help them live healthier lives,” said Neil Haynes, CFO of Sun Life U.S., and board member of the YMCA of Greater Boston. “We are fortunate to work with the Celtics, who have such a wonderful relationship with this community and understand the importance of health equity.”

“Seeing our kids embrace fitness and learn about health from their favorite athletes is extremely inspiring and we hope it helps them build a lifetime of healthy habits,” said David Shapiro, CEO of the YMCA of Greater Boston. “The YMCA is here to help the Boston community live healthier lives, and we could not do that without the support of wonderful partners like Sun Life and the Boston Celtics.”

Fit to Win activities include fitness routines with jumping jacks, push ups, burpees and more; healthy habits such as stretching for 10 minutes daily and practicing mindfulness; and nutrition choices, including eating multiple servings of fruits and vegetables each day. The program is held at multiple Boston YMCAs, for children in third through sixth grade.

Sun Life’s partnership with the Celtics also includes #SunLifeDunk4Diabetes, a fundraising campaign held each November (Diabetes Awareness Month) to support the YMCA of Greater Boston’s Healthy Habits program, a 10-week educational course for adults at risk for type 2 diabetes. Additional diabetes programs include Sun Life’s annual Team Up Against Diabetes grant program, which supports organizations around the country that provide health, nutrition, or disease management services to underserved communities, and an ongoing partnership with the American Diabetes Association.

About Sun Life

Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of September 30, 2022, Sun Life had total assets under management of C$1.27 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Sun Life U.S. is one of the largest providers of employee and government benefits, helping more than 50 million Americans access the healthcare and coverage they need. Through employers, industry partners and government programs, Sun Life offers a portfolio of benefits and services, including dental, vision, disability, absence management, life, supplemental health, medical stop-loss insurance, and healthcare navigation. Sun Life U.S. and affiliated companies in asset management employ approximately 8,000 people in the U.S. Group insurance policies are issued by Sun Life Assurance Company of Canada (Wellesley Hills, Mass.), except in New York, where policies are issued by Sun Life and Health Insurance Company (U.S.) (Lansing, Mich.). For more information visit our website and newsroom.

About the Boston Celtics

A charter member of the Basketball Association of America (which evolved into the National Basketball Association) since 1946, the Boston Celtics have won a record 17 NBA Championships, including eight (8) in a row from 1959-1966, winning their first title in 1957 and their most recent in 2008. The Celtics have long stood for equality and respect, including hiring the first African American Coach and starting the first all-black starting five. In addition, 39 former Celtics players, management or staff have been inducted into the Naismith Memorial Basketball Hall of Fame. In December 2002 the team returned to local ownership for the first time since 1963. For more information, log on to www.celtics.com.

Media contacts:
Devon Fernald
Sun Life U.S.
781-800-3609
[email protected] 

Taylor Kielpinski-Rogers
Boston Celtics
[email protected] 

Connect with Sun Life U.S.

Facebook, LinkedIn and Twitter

SOURCE Sun Life U.S.